Purpose: Present a case of bilateral foveal acute myelogenous leukemic tumors that responded to radiation therapy.
Design: Case report.
Methods: A patient was diagnosed with bilateral subfoveal infiltration of known systemic acute myelogenous leukemia. He received a standard induction chemotherapy, followed by consolidation therapy for his systemic leukemia. However, despite a complete marrow response, the intraocular tumors did not regress. Therefore, he was given low dose (1950-cGy) ocular external beam radiation therapy.
Results: One course of systemic cytarabine chemotherapy failed to control the subfoveal tumors, leaving the patient at risk for permanent vision loss. In contrast, external beam radiation therapy improved his vision from 20/60 in his right eye to 20/20 and from 20/70 in his left eye to 20/25.
Conclusion: Although systemic chemotherapy can be used to treat intraocular metastasis, external beam radiation may provide more prompt resolution of vision-threatening tumors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ajo.2004.04.047 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Accurate prediction of survival in patients with acute myelogenous leukemia (AML) is challenging. Therefore, we developed a predictive survival model using endocrine-related gene expression to identify an endocrine signature for accurate stratification of AML prognosis. RNA matrices and clinical data for AML were downloaded from a training dataset (GEO) and two validation datasets (TCGA and TARGET).
View Article and Find Full Text PDFBackground: Platelets are correlated with myeloid leukemia (ML), but to date, there have been no studies confirming the causal relationship between them.
Methods: Platelet count (PLT), mean platelet volume (MPV), plateletcrit (PCT), and platelet distribution width (PDW) data were obtained from the GWAS catalog database as exposure factors. Acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) data were obtained from the FinnGen database as outcome indicators.
Breaking the Bone Marrow Barrier: Peripheral Blood as a Gateway to Measurable Residual Disease Detection in Acute Myelogenous Leukemia.
Am J Hematol
January 2025
Division of Oncologic Sciences, Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA.
Acute myeloid leukemia (AML) is a genetically heterogeneous disease with high rates of relapse after initial treatment. Identifying measurable residual disease (MRD) following initial therapy is essential to assess response, predict patient outcomes, and identify those in need of additional intervention. Currently, MRD analysis relies on invasive, serial bone marrow (BM) biopsies, which complicate sample availability and processing time and negatively impact patient experience.
View Article and Find Full Text PDFNon-Langerhans cell histiocytosis in a patient with an acute myelogenous leukemia relapse: A case report.
Int J Dermatol
January 2025
Department of Dermatology, American University of Beirut Medical Center, Beirut, Lebanon.
A Case of High-Risk Myelodysplastic Syndrome Revealed After Emergent Aortic Surgery.
Cureus
November 2024
Division of Cardiovascular Surgery, Department of Surgery, Kurume University, Kurume, JPN.
The outcomes of cardiac surgery in patients with hematologic disorders are significantly worse. However, details of the clinical course of each hematologic disease remain unclear. Myelodysplastic syndrome (MDS) presents with progressive pancytopenia that has the risk of infection, hemorrhage, and transformation to acute myelogenous leukemia.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!